Hb H disease: clinical course and disease modifiers
- PMID: 20008179
- DOI: 10.1182/asheducation-2009.1.26
Hb H disease: clinical course and disease modifiers
Abstract
Hemoglobin H (Hb H) disease is the most common form of thalassemia intermedia and has many features that require careful consideration in management. In the majority of cases, Hb H disease results from double heterozygosity for alpha(0)-thalassemia due to deletions that remove both linked alpha-globin genes on chromosome 16, and deletional alpha(+)-thalassemia from single alpha-globin gene deletions (--/-alpha). However, Hb H disease may occur from interactions between alpha(0)-thalassemia with non-deletional mutations (alpha(T)alpha or alpha(T)) or with abnormal hemoglobins such as Hb Constant Spring, Hb Paksé, Hb Quong Sze, and Hb Pak Num Po. In a steady state, patients with Hb H diseases have hemoglobin levels around 9 to 10 g/dL; however, during hemolytic crisis, which frequently develops in or after acute infections with high fever, the hemoglobin level may drop significantly and patients can develop shock or renal shutdown. Even though splenectomy leads to significant elevation of hemoglobin levels, it is not recommended because the majority of patients do well with said steady-state hemoglobin levels. Patients with non-deletional Hb H disease are usually more anemic with significant splenomegaly, and some may require regular blood transfusions and be even as severe as "Hb H hydrops fetalis." However, there is no clear genotype-phenotype correlation associated with this severe clinical syndrome since patients with identical genotypes do not necessary show the same severity. This suggests that other genetic and environmental factors play a role in modifying the degree of clinical severity in patients with non-deletional Hb H disease.
Similar articles
-
Phenotypic variability in a chinese family with nondeletional Hb H-Hb Quong Sze disease.Hemoglobin. 2011;35(4):430-3. doi: 10.3109/03630269.2011.592554. Hemoglobin. 2011. PMID: 21797711
-
Clinical phenotypes and molecular characterization of Hb H-Paksé disease.Haematologica. 2002 Feb;87(2):117-25. Haematologica. 2002. PMID: 11836160
-
The Hematological and Molecular Spectrum of α-Thalassemias in Turkey: The Hacettepe Experience.Turk J Haematol. 2015 Jun;32(2):136-43. doi: 10.4274/tjh.2014.0200. Turk J Haematol. 2015. PMID: 26316481 Free PMC article.
-
Advances in the treatment of alpha-thalassemia.Blood Rev. 2012 Apr;26 Suppl 1:S31-4. doi: 10.1016/S0268-960X(12)70010-3. Blood Rev. 2012. PMID: 22631041 Review.
-
Alpha-thalassemia: Hb H disease and Hb Barts hydrops fetalis.Ann N Y Acad Sci. 2005;1054:25-32. doi: 10.1196/annals.1345.004. Ann N Y Acad Sci. 2005. PMID: 16339648 Review.
Cited by
-
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.Haematologica. 2015 May;100(5):e169-71. doi: 10.3324/haematol.2014.115733. Epub 2015 Jan 16. Haematologica. 2015. PMID: 25596269 Free PMC article. No abstract available.
-
The shortcut strategy for beta thalassemia prevention.Hematol Rep. 2018 May 25;10(2):7530. doi: 10.4081/hr.2018.7530. eCollection 2018 May 14. Hematol Rep. 2018. PMID: 30046413 Free PMC article.
-
Liver iron content determination by magnetic resonance imaging.World J Gastroenterol. 2010 Apr 7;16(13):1587-97. doi: 10.3748/wjg.v16.i13.1587. World J Gastroenterol. 2010. PMID: 20355237 Free PMC article. Review.
-
The Adverse Effects of Pregnancies Complicated by Hemoglobin H (HBH) Disease.Iran J Pathol. 2015 Fall;10(4):318-21. Iran J Pathol. 2015. PMID: 26351505 Free PMC article.
-
Efficient and in situ correction of hemoglobin Constant Spring mutation by prime editing in human hematopoietic cells.Mol Ther Nucleic Acids. 2024 Oct 28;35(4):102371. doi: 10.1016/j.omtn.2024.102371. eCollection 2024 Dec 10. Mol Ther Nucleic Acids. 2024. PMID: 39640014 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources